Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

MDM2 inhibitor

DRUG CLASS:

MDM2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

TP53 wild-type	Acute Myelogenous Leukemia	TP53 wild-type	Acute Myelogenous Leukemia	RG7388 Resistant: B - Late Trials RG7388 Resistant : B	RG7388 Resistant: B - Late Trials RG7388 Resistant : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
MDM2 amplification	Sarcoma	MDM2 amplification	Sarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	HDM201 Sensitive: C2 – Inclusion Criteria HDM201 Sensitive : C2	HDM201 Sensitive: C2 – Inclusion Criteria HDM201 Sensitive : C2
TP53 wild-type	Lymphoma	TP53 wild-type	Lymphoma	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2